Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

DUBLIN, Ireland, March 08, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, will hold an investor webcast Thursday, March 11, at 4:30 PM ET to review three oral presentations made at The 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021).

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

DUBLIN, Ireland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021). Prothena will present new preclinical data demonstrating that targeting a novel epitope with PRX005, an anti-tau antibody, resulted in superior attributes for the potential treatment of Alzheimer's disease. PRX005 is being developed as part of the Company's global neuroscience collaboration with Bristol Myers Squibb. In addition, Roche will present new pre-specified exploratory subgroup analyses from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease and, separately, new digital biomarker data from its remote monitoring technology used in the study. Prasinezumab is being developed as part of the Company's worldwide collaboration with Roche.

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

Bumble

Fiserv

Anterix Inc

Corvus Pharmaceuticals

Decibel Therapeautics

Molecular Templates

NexImmune

Oncorus

Talis Biomedical

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

The stock price of Prothena Corporation PLC (NASDAQ: PRTA) increased by 45.54% on Friday, February 12. This is why it happened.

PRTA Stock Price Increased 45.54%: Why It Happened

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

CollPlant Biotechnologies Ltd - ADR

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

Prothena Corporation (PRTA) CEO Gene Kinney on Q4 2020 Results - Earnings Call Transcript

Shares of Prothena Corp (NASDAQ:PRTA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share decreased 42.59% year over year to ($0.77), which were in line with the estimate of ($0.77).

Recap: Prothena Corp Q4 Earnings

DUBLIN, Ireland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today reported financial results for the fourth quarter and full year 2020. In addition, the Company provided 2021 financial guidance and an update on its R&D programs.

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

DUBLIN, Ireland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will report its fourth quarter and full year 2020 financial results on Thursday, February 11, 2021 before the open of the U.S. financial markets. The announcement will be followed by a live audio conference call at 8:30 AM ET.

Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Prothena (PRTA) Q4 Earnings Expected to Decline

The stock price of Prothena Corporation PLC (NASDAQ: PRTA) has increased by over 25% pre-market today as of 6:19 AM ET. This is why it happened.

PRTA Stock Price Increases Over 25% Pre-Market: Why It Happened

DUBLIN, Ireland, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced that following further analyses by the Company and multiple in-depth discussions with the U.S. Food and Drug Administration (FDA) regarding the previous analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study, Prothena is advancing birtamimab into the confirmatory Phase 3 AFFIRM-AL study in this category of patients with AL amyloidosis. This registration-enabling study will be conducted with a primary endpoint of all-cause mortality at p

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Why Is Prothena (PRTA) Down 19.9% Since Last Earnings Report?

DUBLIN, Ireland, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today reported financial results for the third quarter and first nine months of 2020. In addition, the Company provided an update on its R&D programs.

Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update

DUBLIN, Ireland, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that it will present preclinical data from two programs in its Alzheimer's disease portfolio at the 13th Clinical Trials on Alzheimer's Disease Conference 2020 (CTAD 2020). Prothena's programs being highlighted at CTAD 2020 are next generation anti-Aβ antibodies for subcutaneous administration to improve patient access, and a multi-immunogen vaccine that targets key Aβ and tau epitopes, the two main pathological proteins involved in the cause and progression of Alzheimer's disease, for the prevention and treatment of Alzheimer's Disease. The two programs are part of Prothena's Alzheimer's disease portfolio that includes antibodies, vaccines and small molecules.  

Prothena Announces Presentations on Two Programs from its Alzheimer's Disease Portfolio at CTAD 2020

DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it will report its third quarter and first nine months of 2020 financial results on Wednesday, November 4, after the close of the U.S. financial markets.

Prothena to Report Third Quarter 2020 Financial Results on November 4

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

DUBLIN, Ireland, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that based on positive signals of efficacy consistent with disease modification in the PASADENA study, Roche and Prothena plan to advance prasinezumab into a Phase 2b study in patients with early Parkinson's disease. The study will be designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA to include patients with early Parkinson's disease on stable levodopa therapy. Prasinezumab is the first anti-alpha synuclein antibody to advance into late-stage development. Prothena will earn a $60 million clinical milestone payment upon first patient dosed in this study. Further details are expected to be announced in the first half of 2021.

Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson's Disease

DUBLIN, Ireland, Sept.  15, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investor webcast today at 1:30 PM ET following Roche’s Top Abstract oral presentation of the clinical results from the Phase 2 PASADENA study today at the International Parkinson and Movement Disorder Society's MDS Virtual Congress 2020 (MDS Congress).

Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress

DUBLIN, Ireland, Sept.  11, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), announced that results from the Phase 2 PASADENA study of prasinezumab are being highlighted today at the International Parkinson and Movement Disorder Society's MDS Virtual Congress 2020 (MDS Congress). Prasinezumab is the first potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints in patients with early Parkinson’s disease. As previously reported, the study did not meet the primary objective, but signals of efficacy showing a reduction in disease progression were observed in both of the prasinezumab arms when compared to placebo. In the study, prasinezumab significantly reduced decline in motor function by 35% (pooled dose levels) vs. placebo after one year of treatment on the centrally rated assessment of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, a clinical examination of motor function. Motor symptoms associated with Parkinson’s disease include slowness of movement (bradykinesia), tremor, rigidity, and gait. Prasinezumab-treated patients also demonstrated a significant delay in time to clinically meaningful worsening of motor progression on the site rated assessment of time to at least a 5-point progression on MDS-UPDRS Part III vs. placebo over one year, with a hazard ratio of 0.82 (pooled dose levels). There are currently no treatments available that target the underlying cause of Parkinson’s disease and can slow its progression.

Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study

DUBLIN, Ireland, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that members of its senior management team will present and participate in the 2020 Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 4:00 PM ET. 

Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15

Prothena (PRTA) Up 2.9% Since Last Earnings Report: Can It Continue?

DUBLIN, Ireland, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated timing for the presentation of results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. As previously announced, results from Part 1 of the Phase 2 PASADENA study of prasinezumab were selected as an oral Top Abstract presentation at the upcoming Virtual 2020 International Congress of Parkinson’s Disease and Movement Disorders Society (MDS Congress). The presentation was previously scheduled for September 14 and will now take place on September 15 in a session on Immunotherapies for Proteinopathies.

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders

Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Prothena Stock (PRTA)